Virginia Administrative Code › Title 12 - HEALTH › Agency 5 - DEPARTMENT OF HEALTH › Chapter 90 - REGULATIONS FOR DISEASE REPORTING AND CONTROL › Part XI - Tuberculosis Control › Section 12VAC5-90-225 - Additional data to be reported related to persons with active tuberculosis disease (confirmed or suspected)

Current through Register Vol. 40, No. 24, July 15, 2024
A. Physicians and directors of medical care
				  facilities are required to submit all of the following:
1. An initial report to be completed when
				  there are reasonable grounds to suspect that a person has active TB disease,
				  but no later than when antituberculosis drug therapy is initiated. The reports
				  must include the following: the affected person's name; age; date of birth;
				  gender; address; pertinent clinical, radiographic, microbiologic and pathologic
				  reports, whether pending or final; such other information as may be needed to
				  locate the patient for follow-up; and name, address, and telephone number of
				  the treating physician.
2. A
				  secondary report to be completed simultaneously or within one to two weeks
				  following the initial report. The report must include:
(i) the date, method, and results of tests
				  for tuberculosis infection;
(ii)
				  the date and results of the initial and any follow-up chest
				  radiographs;
(iii) the dates and
				  results of bacteriologic or pathologic testing, the antituberculosis drug
				  regimen, including names of the drugs, dosages and frequencies of
				  administration, and start date;
(iv) the date and results of drug
				  susceptibility testing;
(v) HIV
				  status;
(vi) contact screening
				  information; and
(vii) name,
				  address, and telephone number of treating physician.
3. Subsequent reports are to be made when
				  updated information is available. Subsequent reports are required when clinical
				  status changes, the treatment regimen changes; treatment ceases for any reason;
				  or there are any updates to laboratory results, treatment adherence, name,
				  address, and telephone number of current provider, patient location or contact
				  information, or other additional clinical information.
4. Physicians or directors of medical care
				  facilities responsible for the care of a patient with active tuberculosis
				  disease are required to develop and maintain a written treatment plan. This
				  plan must be in place no later than the time when antituberculosis drug therapy
				  is initiated. Patient adherence to this treatment plan must be documented. The
				  treatment plan and adherence record are subject to review by the local health
				  director or his designee at any time during the course of treatment.
5. The treatment plan for the following
				  categories of patients must be submitted to the local health director or his
				  designee for approval no later than the time when antituberculosis drug therapy
				  is started or modified:
a. For individuals who
				  are inpatients or incarcerated, the responsible provider or facility must
				  submit the treatment plan for approval prior to discharge or
				  transfer.
b. Individuals, whether
				  inpatient, incarcerated, or outpatient, who also have one of the following
				  conditions:
(1) HIV infection.
(2) Known or suspected active TB disease
				  resistant to rifampin, rifabutin, rifapentine or other rifamycin with or
				  without resistance to any other drug.
(3) A history of prior treated or untreated
				  active TB disease, or a history of relapsed active TB disease.
(4) A demonstrated history of nonadherence to
				  any medical treatment regimen.